ReviewBioconjugate chemistry2026
Linker Chemistry in Radiopharmaceutical Design.
Review in Bioconjugate chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board.EJNMMI radiopharmacy and chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Over the last half century, molecularly targeted bioconjugates have revolutionized nuclear medicine. An array of vectors, ranging from small molecule peptidomimetics to macromolecular immunoglobulins, has been radiolabeled with radionuclides to create probes that have been deployed in both the laboratory and the clinic for positron emission tomography (PET), single photon emission computed tomography (SPECT), and radiopharmaceutical therapy. Generally speaking, these compounds have four constituent parts: (i) a targeting vector; (ii) a radionuclide; (iii) a labeling moiety, such as a chelator for radiometals or a prosthetic group for radiohalogens; and (iv) a linker that connects the vector and the labeling moiety. Each of these parts is critical to the performance of the radiopharmaceutical, but the importance of the former─the linker─can be lost in the shadow of its flashier teammates. Strictly speaking, the linker's job is simple: stably connect the vector and the radiolabeling moiety so that they do not become detached
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.